JP2016505635A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505635A5
JP2016505635A5 JP2015554209A JP2015554209A JP2016505635A5 JP 2016505635 A5 JP2016505635 A5 JP 2016505635A5 JP 2015554209 A JP2015554209 A JP 2015554209A JP 2015554209 A JP2015554209 A JP 2015554209A JP 2016505635 A5 JP2016505635 A5 JP 2016505635A5
Authority
JP
Japan
Prior art keywords
seq
nos
cell
tcr
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015554209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505635A (ja
JP6639233B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/051726 external-priority patent/WO2014118236A2/en
Publication of JP2016505635A publication Critical patent/JP2016505635A/ja
Publication of JP2016505635A5 publication Critical patent/JP2016505635A5/ja
Application granted granted Critical
Publication of JP6639233B2 publication Critical patent/JP6639233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015554209A 2013-01-29 2014-01-29 Mage−a1を認識する高結合活性結合分子 Active JP6639233B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13153081 2013-01-29
EP13153081.8 2013-01-29
PCT/EP2014/051726 WO2014118236A2 (en) 2013-01-29 2014-01-29 High avidity antigen recognizing constructs

Publications (3)

Publication Number Publication Date
JP2016505635A JP2016505635A (ja) 2016-02-25
JP2016505635A5 true JP2016505635A5 (https=) 2017-03-09
JP6639233B2 JP6639233B2 (ja) 2020-02-05

Family

ID=47623953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015554209A Active JP6639233B2 (ja) 2013-01-29 2014-01-29 Mage−a1を認識する高結合活性結合分子

Country Status (13)

Country Link
US (3) US10377808B2 (https=)
EP (2) EP2951202B1 (https=)
JP (1) JP6639233B2 (https=)
CN (1) CN105377886B (https=)
AU (2) AU2014211454B2 (https=)
CA (1) CA2899679C (https=)
DK (1) DK2951202T3 (https=)
ES (1) ES2804538T3 (https=)
HU (1) HUE050390T2 (https=)
PL (1) PL2951202T3 (https=)
PT (1) PT2951202T (https=)
SI (1) SI2951202T1 (https=)
WO (1) WO2014118236A2 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2670848B1 (en) 2011-02-06 2016-02-03 Yeda Research and Development Co. Ltd Affinity maturated t cell receptors and use thereof
CN107074970B (zh) * 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
CA2998270A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520544D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3219800A1 (en) 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
PL3440105T3 (pl) * 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
CA3021572A1 (en) * 2016-04-20 2017-10-26 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Compositions and methods for enhanced gene expression of pklr
CN106084042B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗MAGEA1的全分子IgG抗体及其应用
CN110088128B (zh) * 2016-09-23 2023-11-28 来恩生物医药私人有限公司 Hbv抗原特异性结合分子及其片段
HUE058957T2 (hu) * 2016-12-08 2022-10-28 Immatics Biotechnologies Gmbh Új T-sejt receptorok és velük végzett immunterápia
DE102016123847B3 (de) 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术(广东)有限公司 源自于mage b6的肿瘤抗原短肽
MX2019010972A (es) * 2017-03-15 2019-12-02 Hutchinson Fred Cancer Res Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
CN108929378B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别prame抗原的t细胞受体及编码该受体的核酸
CN111655280B (zh) 2017-09-01 2025-01-14 达纳-法伯癌症研究所股份有限公司 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
WO2020172332A1 (en) * 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
TWI850360B (zh) 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原1(magea1)特異性t細胞受體及其用途
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
WO2021005108A1 (en) * 2019-07-09 2021-01-14 Medigene Immunotherapies Gmbh Magea10 specific t cell receptors and their use
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
KR20260017503A (ko) 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
CA3188143A1 (en) * 2020-06-25 2021-12-30 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
IL276599A (en) * 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN112279908B (zh) * 2020-10-23 2024-03-19 魏放 识别ebv抗原短肽的t细胞受体及其应用
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用FLT3L—Fc融合蛋白之方法
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
EP4430402A1 (en) 2021-11-09 2024-09-18 T-Knife GmbH Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN116063457A (zh) * 2022-04-27 2023-05-05 恒瑞源正(广州)生物科技有限公司 Mage-a1特异性t细胞受体及其用途
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
CA3265218A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
WO2025027088A1 (en) 2023-07-31 2025-02-06 T-Knife Gmbh An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
AU2024317975A1 (en) 2023-07-31 2026-02-05 T-Knife Gmbh A chimeric human cd8 co-receptor, a nucleic acid encoding the chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
AU2024332117A1 (en) 2023-08-25 2026-02-12 T-Knife Gmbh Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025096983A1 (en) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025146286A1 (en) 2024-01-04 2025-07-10 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025190565A1 (en) 2024-03-13 2025-09-18 T-Knife Gmbh A chimeric programmed cell death protein 1 receptor
WO2025191067A1 (en) 2024-03-13 2025-09-18 T-Knife Gmbh A chimeric transmembrane receptor comprising at least one t-cell immunoreceptor with ig and itim domains (tigit) polypeptide region, t-cells expressing the chimeric human tigit switch receptor, vectors with nucleic acids encoding for the tigit receptor, kits for preparing the t-cells, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease and for increasing cytotoxicity of a t-cell in adoptive cell therapy
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023164A1 (en) 1994-02-23 1995-08-31 Akzo Nobel N.V. A t cell receptor sequence specifically associated with an immune disease
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Similar Documents

Publication Publication Date Title
JP2016505635A5 (https=)
JP2019511222A5 (https=)
JP2018535668A5 (https=)
CN105384825B (zh) 一种基于单域抗体的双特异性嵌合抗原受体及其应用
HRP20241228T1 (hr) T stanični receptori i imunološka terapija uporabom istih protiv pram pozitivnih karcinoma
KR20230079259A (ko) Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도
JP2020500523A5 (https=)
JP2020532965A5 (https=)
JP2020511152A5 (https=)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
FI3430030T3 (fi) Transfektoituja t-soluja ja t-solureseptoreita käytettäviksi syöpien immunoterapiassa
JP2018527919A5 (https=)
JP2017528158A5 (https=)
JP2020500525A5 (https=)
JP2012525128A5 (https=)
FI3294333T4 (fi) Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit
JP2017029157A5 (https=)
JP2020512019A5 (https=)
JP2018509163A5 (https=)
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
JP2017532952A5 (https=)
JP2013107899A5 (https=)
JP2015525208A5 (https=)
JP2019530440A5 (https=)